Literature DB >> 27262238

Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition.

Brennan C Kahan1, Caroline J Doré2, Michael F Murphy3, Vipul Jairath4.   

Abstract

OBJECTIVE: To determine whether modifying an outcome definition to remove subjective elements reduced bias in a trial that could not use blinded outcome assessment. STUDY DESIGN AND
SETTING: Reanalysis of an open-label trial comparing a restrictive vs. liberal transfusion strategy for gastrointestinal bleeding. The usual definition of the primary outcome, further bleeding, allows subjective clinical symptoms to be used alone for diagnosis, whereas the definition used in the trial required more objective confirmation by endoscopy. We compared treatment effect estimates for these two definitions.
RESULTS: Fewer subjective symptom-identified events were confirmed using more objective methods in the restrictive arm (18%) than in the liberal arm (56%), indicating differential assessment between arms. An analysis using all events (both subjective and more objective) led to an odds ratio of 0.83 (95% confidence interval [CI]: 0.50-1.37). When only events confirmed using more objective methods were included, the odds ratio was 0.50 (95% CI: 0.32-0.78). The ratio of the odds ratios was 1.66, indicating that including unconfirmed events in the definition biased the treatment effect upward by 66%.
CONCLUSION: Modifying the outcome definition to exclude subjective elements substantially reduced bias. This may be a useful strategy for reducing bias in trials that cannot blind outcome assessment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bias; Blinding; Cluster-randomized; Open-label trial; Outcome assessment; Randomized controlled trial

Mesh:

Year:  2016        PMID: 27262238     DOI: 10.1016/j.jclinepi.2016.05.008

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  2 in total

1.  Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.

Authors:  Dionna J Green; Janelle M Burnham; Paul Schuette; Xiaomei I Liu; Brian M Maas; Lynne Yao; Susan K McCune; Joseph Chen; John N van den Anker; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2018-04-17       Impact factor: 3.126

2.  Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists.

Authors:  Igal Kushnir; Mark Clemons; Dean Fergusson; Dominick Bossé; Martin Neil Reaume
Journal:  J Eval Clin Pract       Date:  2022-02-21       Impact factor: 2.336

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.